论文部分内容阅读
目的探讨细胞分化抗原胞浆CD79a(CyCD79a)在各型急性白血病细胞上的表达情况及其意义。方法选取2003年1月至2004年4月河北医科大学第二医院急性白血病患者214例及外院选检病例标本7例,采用CD45/SSC双参数散点图设门方法和三色流式细胞术,对急性白血病患者221例各型急性白血病的细胞免疫表型CyCD79a等B系分化抗原进行检测,比较各型急性白血病患者的表达率。结果急性B淋巴细胞白血病(B-ALL)患者CyCD79a表达率为100%(57/57),高于CD10、CD19、CD20和胞浆CD22(CyCD22)等其他B系分化抗原表达率;急性髓细胞白血病(AML)患者CyCD79a表达率为0.7%(1/134),低于或等于上述其他B系分化抗原表达率;急性T淋巴细胞白血病(T-ALL)患者CyCD79a表达率则为13.3%(2/15)。结论Cy-CD79a对B-ALL具有较高的敏感性和较好的特异性。因此,CyCD79a可以作为诊断B-ALL的一线和首选免疫标志,并可用于B-ALL与T-ALL和AML的鉴别诊断。
Objective To investigate the expression of cytoplasmic CD79a (CyCD79a) on acute leukemia cells and its significance. Methods From January 2003 to April 2004, 214 acute leukemia patients from the Second Hospital of Hebei Medical University and 7 cases from the outpatient checkup were selected. CD45 / SSC double-parameter scatter-plot method and three-color flow cytometry , 221 acute leukemia patients with various types of acute leukemia cell immunophenotype CyCD79a and other B-lineage antigen was detected in patients with various types of acute leukemia expression rate. Results The positive rate of CyCD79a expression in B-ALL patients was 100% (57/57), which was higher than that of other B-type differentiation antigens such as CD10, CD19, CD20 and CyCD22. Acute myelocytic CyCD79a expression in patients with leukemia (AML) was 0.7% (1/134), which was lower than or equal to the expression rates of other B-lineage differentiated antigens. The expression of CyCD79a in patients with acute lymphoblastic leukemia (T-ALL) / 15). Conclusion Cy-CD79a has high sensitivity and good specificity to B-ALL. Therefore, CyCD79a can be used as a first-line and first-line immunological marker for B-ALL diagnosis and can be used for the differential diagnosis between B-ALL and T-ALL and AML.